MAPK1
Reaktivität: Human
WB, ELISA, IHC, IF
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Western Blot: 1: 500- 1: 2,000 IHC(P): 1: 500- 1: 2,000 IHC(F): 1: 500- 1: 2,000 ELISA: Propose dilution 1: 10,000. Determining optimal working dilutions by titration test.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Lagerung
-20 °C
Whitehurst, Robinson, Moore, Cobb: "The death effector domain protein PEA-15 prevents nuclear entry of ERK2 by inhibiting required interactions." in: The Journal of biological chemistry, Vol. 279, Issue 13, pp. 12840-7, (2004) (PubMed).
Begum, Asghar, N, Khan, Khan: "High dose rate intraluminal brachytherapy in combination with external beam radiotherapy for palliative treatment of cancer rectum." in: Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, Vol. 13, Issue 11, pp. 633-6, (2003) (PubMed).
Target
ERK2 (MAPK1)
(Mitogen-Activated Protein Kinase 1 (MAPK1))
ERK2 (also designated extracellular-signal-related kinase 2 or mitogen-activated protein kinase 1), with 360-amino acid protein (about 40kDa), belongs to the MAP kinase family. MAP kinases act as an integration point for multiple biochemical signals, and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. The activation of ERK2 requires its phosphorylation by upstream kinases. ERK2 is located in the cytoplasm of resting cells and translocates into the nucleus upon extracellular stimuli by active transport of a dimer. ERK2 is essential for placental development and ERK2 in the trophoblast compartment may be indispensable for the vascularization of the labyrinth.